Hyaluronic acid sodium salt (Sodium hyaluronate)
(Synonyms: 透明质酸钠; Sodium hyaluronate) 目录号 : GC32941
Sodium hyaluronate is the sodium salt of hyaluronic acid, a glycosaminoglycan found in various connective tissue of humans.
Cas No.:9067-32-7
Sample solution is provided at 25 µL, 10mM.
;)
,-1-7$$$37316672.jpg');)
;)
;)
$$$36806353.jpg');)
;33(7)%EF%BC%9A546-561$$$37156877.jpg');)
;)
;)
;)
%201124-1138.$$$35908550.jpg');)
%20766-780.$$$37100057.jpg');)
%20418-432.$$$36893736.jpg');)
%EF%BC%9A-240-255.$$$35108512.jpg');)
533-545$$$36543525.jpg');)
%201-13.$$$36600053.jpg');)
;)
Quality Control & SDS
- View current batch:
- Purity: >99.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
Sodium hyaluronate is the sodium salt of hyaluronic acid, a glycosaminoglycan found in various connective tissue of humans.
| Cas No. | 9067-32-7 | SDF | |
| 别名 | 透明质酸钠; Sodium hyaluronate | ||
| Canonical SMILES | [*]CC1[C@@H](O)[C@@H](O)O[C@@H](O[C@H]2[C@H](C([O-])=O)OC(O[*])[C@@H](O)[C@@H]2O)[C@@H]1NC(C)=O.[Na+] | ||
| 分子式 | n*(C14H21NaNO11) | 分子量 | 403.31 |
| 溶解度 | Water : 6.8 mg/mL | 储存条件 | Store at -20°C |
| General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液；一旦配成溶液，请分装保存，避免反复冻融造成的产品失效。 储备液的保存方式和期限：-80°C 储存时，请在 6 个月内使用，-20°C 储存时，请在 1 个月内使用。 为了提高溶解度，请将管子加热至37℃，然后在超声波浴中震荡一段时间。 |
||
| Shipping Condition | 评估样品解决方案：配备蓝冰进行发货。所有其他可用尺寸：配备RT，或根据请求配备蓝冰。 | ||
| 制备储备液 | |||
 |
1 mg | 5 mg | 10 mg |
| 1 mM | 2.4795 mL | 12.3974 mL | 24.7948 mL |
| 5 mM | 0.4959 mL | 2.4795 mL | 4.959 mL |
| 10 mM | 0.2479 mL | 1.2397 mL | 2.4795 mL |
| 第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量） | ||||||||||
| 给药剂量 | mg/kg |  |
动物平均体重 | g | |
每只动物给药体积 | ul | |
动物数量 | 只 |
| 第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系GLPBIO为您提供正确的澄清溶液配方） | ||||||||||
| % DMSO % % Tween 80 % saline | ||||||||||
| 计算重置 | ||||||||||
计算结果:
工作液浓度： mg/ml；
DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，
体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL saline，混匀澄清。
1. 首先保证母液是澄清的；
2.
一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。
Trehalose/Sodium hyaluronate eye drops in post-cataract ocular surface disorders
Int Ophthalmol 2021 Sep;41(9):3065-3071.PMID:33956256DOI:10.1007/s10792-021-01869-z.
Purpose: Prospective, randomised, open-label, comparative study to evaluate efficacy of trehalose/Sodium hyaluronate eye drops for post-operative discomfort and tear film stability in patients undergoing cataract surgery. Methods: Patients with healthy ocular surface, subclinical, or mild dry eye were enrolled. Tear breakup time (TBUT), Schirmer test, dry eye symptoms, corneal fluorescein staining (CFS), and ocular surface disease (OSDI) evaluation were performed pre-operatively and at two and four weeks after surgery. Patients were assigned to receive trehalose/Sodium hyaluronate eye drops b.i.d (Group A), or 0.9% unpreserved sodium chloride eye drops b.i.d for 4 weeks (Group B). Results: One hundred and thirty-five patients were randomised, 66 patients in Group A (73.2 ± 4.5 years) and 69 patients in Group B (74.3 ± 3.8 years), 60.8% females. Fifteen patients (8 Group A) were lost at follow-up. Pre-operatively, no between-group differences were observed, and TBUT increased in Group A between the pre-operative and 2 and 4 week evaluations and was higher in group A than in Group B at 4 weeks. Schirmer test and CFS showed an improvement only in Group A four weeks post-operatively. In Group A an improvement was observed after two and four weeks in foreign body and puncture sensation, whilst a difference in blinking discomfort was observed after four weeks. In Group B we observed an improvement in puncture sensation two and four weeks after surgery. Mean OSDI scores differences between the two groups were significant at four weeks. Conclusions: Trehalose/Sodium hyaluronate eye drops were effective in reducing signs and symptoms of dry eye and improving tear film stability.
[Effects of Benzalkonium Chloride in Ophthalmic Eyedrop Medications on Corneal Epithelium]
Yakugaku Zasshi 2021;141(1):35-39.PMID:33390445DOI:10.1248/yakushi.20-00177-1.
Eyedrops often contain additives other than active pharmaceutical ingredients, such as preservatives. The most frequently used preservative is benzalkonium chloride (BAC). When the ocular surface is exposed to eyedrops, the active pharmaceutical ingredients and additives can cause corneal epithelial disorder. Particularly in clinical settings, there is great interest in corneal epithelial disorders resulting from the use of glaucoma eyedrops, which is inevitable when instilled for a long period of time after the onset of disease. At the authors' institute, glaucoma is treated with consideration of reducing corneal epithelial disorder while ensuring the effect of lowering intraocular pressure by the appropriate choice of eyedrops. In this review, we show the examples of the retrospective studies. Sodium hyaluronate eyedrops are prescribed for corneal epithelial disorders such as superficial punctate keratitis associated with dry eye. Prescribable concentrations of Sodium hyaluronate in Japan are 0.1% or 0.3%, and the 0.3% formulation does not contain BAC. The authors' study showed that 0.3% Sodium hyaluronate pretreatment reduced the cytotoxicity of BAC in cultured corneal epithelial cells, whereas an in vivo study in mice showed that a 0.3% Sodium hyaluronate instillation was suggested and that the drug may enhance the cytotoxicity of separately administered BAC. It is suggested that Sodium hyaluronate prolonged the retention of BAC on the ocular surface. However, there have been no reports of this problem in the clinical setting. It is important for ophthalmologists to understand the properties of additives other than the active pharmaceutical ingredients in eyedrops.
Hyaluronic acid sodium salt 0.2% Gel in the Treatment of a Recalcitrant Distal Leg Ulcer: A Case Report
J Clin Aesthet Dermatol 2017 Nov;10(11):49-51.PMID:29399261doi
Venous leg ulcers can lead to debilitation and a decrease in quality of life and can require costly treatments. Compression therapy remains the foundation of conservative treatment. However, some ulcers become indolent, chronic, and unresolved for years, even with adherence to standard of care. Here, the authors describe the case of a 56-year-old male patient with a recalcitrant recurrent distal leg ulcer. The ulcer was treated initially with debridement and compression therapy, respectively, and then subsequently with Hyaluronic acid sodium salt 0.2% gel, which prompted complete wound closure. Hyaluronic acid is known to stimulate angiogenesis and exert fibrogenic action within inflamed and impaired healing tissues. Only a limited number of studies have been conducted to evaluate the clinical use of hyaluronic acid for treating venous leg ulcers. Success obtained with this patient should spur future clinical studies to fully evaluate this modality as a safe, efficacious, expeditious, and cost-effective option for the management of recalcitrant chronic ulcers.
Efficacy and tolerability of low molecular weight Hyaluronic acid sodium salt 0.2% cream in rosacea
J Drugs Dermatol 2013 Jun 1;12(6):664-7.PMID:23839183doi
Objective: Rosacea is a chronic cutaneous disorder characterized by flushing, erythema, telangiectasia, edema, papules, and pustules. The cause of this inflammatory disorder is unknown, but is thought to be multifaceted. Primary treatments for rosacea are typically oral antibiotics and topical therapies. Hyaluronic acid sodium salt cream 0.2% is a topical device containing low molecular weight hyaluronic acid (LMW-HA) that is effective in normalizing the cutaneous inflammatory response. The objective of this study was to evaluate the efficacy and safety of Hyaluronic acid sodium salt cream 0.2%. Design and setting: Prospective, observational, non-blinded efficacy and tolerability study in an outpatient setting. Participants: Individuals 18 to 75 years of age with mild to moderate facial rosacea. Measurements: Outcome measures included papules, pustules, erythema, edema, telangiectasia, burning or stinging, dryness and provider global assessment (PGA), which were all measured on a five-point scale. Subjects were assessed at baseline, week 2, week 4, and week 8. Results: Final data for 14 of 15 subjects are presented. Through visual grading assessments, Hyaluronic acid sodium salt cream 0.2% was shown to improve the provider global assessment by 47.5 percent from baseline to week 4. Reductions in papules, erythema, burning or stinging, and dryness were 47, 51.7, 65, and 78.8 percent, respectively at week 4. At week 8, the provider global assessment was improved from baseline in 78.5 percent of subjects. Conclusion: Improvement was noted in measured clinical parameters with use of topical low molecular weight hyaluronic acid. Topical low molecular weight hyaluronic acid is another option that may be considered for the treatment of rosacea in the adult population. Compliance and tolerance were excellent. Consideration should be given to use for individuals with rosacea characterized by an erythematous and/or papular component.
Hyaluronic Acid/Chitosan Coacervate-Based Scaffolds
Biomacromolecules 2018 Apr 9;19(4):1198-1211.PMID:29554416DOI:10.1021/acs.biomac.8b00047.
Chitosan-chloride (CHI) and Sodium hyaluronate (HA), two semiflexible biopolymers, self-assemble to form nonstoichiometric coacervates. The effect of counterions was briefly investigated by preparing HA/CHI coacervates in either CaCl2 or NaCl solutions to find only a small difference in their tendency to coacervate. Higher water content in coacervates within CaCl2 was attributed to the chaotropic nature of Ca2+ ions. This effect was also evidenced with smaller pore sizes for coacervates in NaCl. Besides, for coacervation of chitosan-glutamate (CHI-G) with HA, dynamic light scattering at different charge ratios indicated a wider coacervation region for the HA/CHI-G pair than the HA/CHI. This was attributed to the chaotropic and "soft" ion nature of glutamate compared to chloride as a counterion of chitosan. Positive zeta potential values for both coacervate suspensions were explained by the contribution of charge mismatch, chain semiflexibility, and intra- and intercomplex disproportionation. Finally, HA/CHI coacervates were used to encapsulate bone marrow stem cells. While cell viabilities in HA/CHI coacervates were remarkable up to 21 days, their well-spread morphology has proved that HA/CHI coacervates are promising scaffolds for cartilage tissue engineering.